View Future GrowthRootK 과거 순이익 실적과거 기준 점검 0/6RootK 의 수입은 연평균 -19.3%의 비율로 감소해 온 반면, Machinery 산업은 연평균 18.3%의 비율로 증가했습니다. 매출은 연평균 2.5%의 비율로 감소해 왔습니다.핵심 정보-19.31%순이익 성장률-16.57%주당순이익(EPS) 성장률Machinery 산업 성장률18.85%매출 성장률-2.49%자기자본이익률-76.62%순이익률-140.89%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.모든 업데이트 보기Recent updates공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).분석 기사 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).분석 기사 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...분석 기사 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).공시 • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea분석 기사 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).분석 기사 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).분석 기사 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).공시 • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).분석 기사 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.공시 • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.분석 기사 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.분석 기사 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.매출 및 비용 세부 내역RootK가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A195990 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2630,937-43,5859,86842831 Dec 2531,923-48,92010,96543730 Sep 2536,183-70,0297,17639530 Jun 2541,588-61,3406,86035031 Mar 2534,429-18,1687,08440531 Dec 2431,663-15,6295,50144830 Sep 2427,416-6,89210,28150030 Jun 2418,585-20,16210,38357331 Mar 2423,327-22,4529,33255731 Dec 2325,375-25,7429,83257330 Sep 2325,836-16,07410,76667430 Jun 2325,873-11,93311,16666031 Mar 2324,851-10,47511,61676731 Dec 2222,112-8,14511,11788030 Sep 2220,595-11,9378,27678830 Jun 2224,674-6,5907,77381231 Mar 2226,136-11,1698,96469231 Dec 2132,914-9,2557,78356230 Sep 2142,613-33,6318,11156330 Jun 2145,552-37,6167,18355331 Mar 2143,897-39,6675,38156331 Dec 2035,797-42,1106,04151930 Sep 2024,386-29,5747,6901,24030 Jun 2015,585-40,7428,2181,76831 Mar 2020,995-33,92511,1831,85731 Dec 1931,930-32,72412,4561,98530 Sep 1936,110-20,84210,2621,62730 Jun 1953,787-9,33711,46095331 Mar 1960,322-10,8119,38298731 Dec 1858,857-9,3908,6591,21330 Sep 1866,323-7,13611,58396430 Jun 1854,066-11,11811,73996431 Mar 1850,929-7,44911,81898031 Dec 1745,944-11,62612,0521,36930 Sep 1738,589-8,26711,3841,58530 Jun 1742,120-6,12511,6451,58531 Mar 1743,467-4,61511,1211,62931 Dec 1649,5211710,2691,54030 Sep 1653,1282,5818,0501,45330 Jun 1650,7683,7946,8161,45331 Mar 1664,1305,6017,4041,42631 Dec 1577,10115,0217,3701,49830 Sep 1595,49619,5678,7901,416양질의 수익: A195990 은(는) 현재 수익성이 없습니다.이익 마진 증가: A195990는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A195990은 수익성이 없으며 지난 5년 동안 손실이 연평균 19.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A195990의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A195990은 수익성이 없어 지난 해 수익 성장률을 Machinery 업계(39.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A195990는 현재 수익성이 없으므로 자본 수익률이 음수(-76.62%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 09:30종가2026/06/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스RootK Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.
공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.
Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).
분석 기사 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).
분석 기사 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...
분석 기사 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).
New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).
공시 • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea
분석 기사 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...
New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).
분석 기사 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).
분석 기사 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...
New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).
공시 • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).
분석 기사 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
공시 • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.
분석 기사 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
분석 기사 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...
Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.
Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.